Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105201781> ?p ?o ?g. }
- W2105201781 endingPage "1037" @default.
- W2105201781 startingPage "1017" @default.
- W2105201781 abstract "Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is relatively higher in women compared with men. The treatment of OAB is aimed at reducing the debilitating symptoms so as to improve the overall quality of life for patients. Anticholinergic agents targeting the muscarinic receptors in the bladder represent the mainstay of pharmacotherapy for the treatment of OAB. Besides their status as the current standard of care, use of antimuscarinic drugs is limited by certain side effects, particularly dry mouth and constipation; therefore, various attempts have been made to improve the organ selectivity of these drugs to overcome the side effects. These include the development of new antimuscarinic agents with structural modifications and the use of innovative drug delivery methods. The advancement in the drug delivery systems extends to the long-term therapeutic efficacy with improved tolerability and patient compliance; however, future prospective therapies are aimed at novel targets with novel mechanisms of action, including β3-adrenoceptor agonists, K+ channel openers, 5-HT modulators and botulinum toxin, which are currently under different stages of clinical development. Among other investigational therapies, neurokinin receptor antagonists, α-adrenoceptor antagonists, nerve growth factor inhibitors, gene therapy and stem cell-based therapies are of considerable interest. The future for the development of new modalities for the treatment of OAB looks promising." @default.
- W2105201781 created "2016-06-24" @default.
- W2105201781 creator A5017005427 @default.
- W2105201781 creator A5083614802 @default.
- W2105201781 date "2006-08-17" @default.
- W2105201781 modified "2023-10-03" @default.
- W2105201781 title "Current and emerging investigational medical therapies for the treatment of overactive bladder" @default.
- W2105201781 cites W1257881779 @default.
- W2105201781 cites W1496249181 @default.
- W2105201781 cites W1525819881 @default.
- W2105201781 cites W1545422366 @default.
- W2105201781 cites W1591365506 @default.
- W2105201781 cites W1821426726 @default.
- W2105201781 cites W182181281 @default.
- W2105201781 cites W1938705645 @default.
- W2105201781 cites W1963545228 @default.
- W2105201781 cites W1967312126 @default.
- W2105201781 cites W1968860914 @default.
- W2105201781 cites W1971566600 @default.
- W2105201781 cites W1971788892 @default.
- W2105201781 cites W1971867200 @default.
- W2105201781 cites W1973361531 @default.
- W2105201781 cites W1973849826 @default.
- W2105201781 cites W1976051331 @default.
- W2105201781 cites W1976363592 @default.
- W2105201781 cites W1980007713 @default.
- W2105201781 cites W1980809057 @default.
- W2105201781 cites W1983188206 @default.
- W2105201781 cites W1985843619 @default.
- W2105201781 cites W1986794284 @default.
- W2105201781 cites W1986950108 @default.
- W2105201781 cites W1989309123 @default.
- W2105201781 cites W1989542911 @default.
- W2105201781 cites W1990266903 @default.
- W2105201781 cites W1994653403 @default.
- W2105201781 cites W1996537024 @default.
- W2105201781 cites W1997044455 @default.
- W2105201781 cites W1999515762 @default.
- W2105201781 cites W2001374375 @default.
- W2105201781 cites W2002406661 @default.
- W2105201781 cites W2003700491 @default.
- W2105201781 cites W2007886796 @default.
- W2105201781 cites W2011917402 @default.
- W2105201781 cites W2011994411 @default.
- W2105201781 cites W2012563222 @default.
- W2105201781 cites W2016589301 @default.
- W2105201781 cites W2017417965 @default.
- W2105201781 cites W2019362433 @default.
- W2105201781 cites W2019416837 @default.
- W2105201781 cites W2020588358 @default.
- W2105201781 cites W2022504623 @default.
- W2105201781 cites W2023670307 @default.
- W2105201781 cites W2024975356 @default.
- W2105201781 cites W2024991118 @default.
- W2105201781 cites W2026599479 @default.
- W2105201781 cites W2028462700 @default.
- W2105201781 cites W2029074543 @default.
- W2105201781 cites W2031151714 @default.
- W2105201781 cites W2040987700 @default.
- W2105201781 cites W2042125279 @default.
- W2105201781 cites W2043742417 @default.
- W2105201781 cites W2044154060 @default.
- W2105201781 cites W2044632947 @default.
- W2105201781 cites W2049903313 @default.
- W2105201781 cites W2051448097 @default.
- W2105201781 cites W2052790257 @default.
- W2105201781 cites W2054469479 @default.
- W2105201781 cites W2057606215 @default.
- W2105201781 cites W2060100976 @default.
- W2105201781 cites W2060209468 @default.
- W2105201781 cites W206077478 @default.
- W2105201781 cites W2061333755 @default.
- W2105201781 cites W2061787346 @default.
- W2105201781 cites W2063574029 @default.
- W2105201781 cites W2064179716 @default.
- W2105201781 cites W2064430566 @default.
- W2105201781 cites W2064573542 @default.
- W2105201781 cites W2065027603 @default.
- W2105201781 cites W2068922363 @default.
- W2105201781 cites W2070432389 @default.
- W2105201781 cites W2070500689 @default.
- W2105201781 cites W2071142898 @default.
- W2105201781 cites W2071849407 @default.
- W2105201781 cites W2073149905 @default.
- W2105201781 cites W2074207497 @default.
- W2105201781 cites W2079675222 @default.
- W2105201781 cites W2081116963 @default.
- W2105201781 cites W2081989208 @default.
- W2105201781 cites W2083272868 @default.
- W2105201781 cites W2084631435 @default.
- W2105201781 cites W2085588502 @default.
- W2105201781 cites W2087444995 @default.
- W2105201781 cites W2087695411 @default.
- W2105201781 cites W2087764890 @default.
- W2105201781 cites W2088625680 @default.
- W2105201781 cites W2089322299 @default.
- W2105201781 cites W2090219919 @default.
- W2105201781 cites W2090247886 @default.